MXPA03001812A - Modulacion de la expresion del sindrome de alcohol fetal y del ligando del sindrome de alcohol fetal.. - Google Patents

Modulacion de la expresion del sindrome de alcohol fetal y del ligando del sindrome de alcohol fetal..

Info

Publication number
MXPA03001812A
MXPA03001812A MXPA03001812A MXPA03001812A MXPA03001812A MX PA03001812 A MXPA03001812 A MX PA03001812A MX PA03001812 A MXPA03001812 A MX PA03001812A MX PA03001812 A MXPA03001812 A MX PA03001812A MX PA03001812 A MXPA03001812 A MX PA03001812A
Authority
MX
Mexico
Prior art keywords
modulation
fas
fasl expression
efficacy
modulate
Prior art date
Application number
MXPA03001812A
Other languages
English (en)
Inventor
C Philips Nigel
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2000/001467 external-priority patent/WO2001044465A2/en
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Publication of MXPA03001812A publication Critical patent/MXPA03001812A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)

Abstract

Un metodo de empleo de una composicion que comprende una secuencia de oligonucleotido sintetico de 2 a 10 bases seleccionada del grupo que consiste de: (GG)n, (GT)n, a(GT)nb, a(GA)nb, y a(GC)nb, en donde n es un entero de entre 1 y 3, y a y b son independientemente de ya sea ninguno o 1 o mas de As, Cs, Gs, o Ts, o una combinacion de los mismos para la modulacion del Sindrome de Alcohol Fetal y de la expresion de ligando de Sindrome de Alcohol Fetal o para la modulacion de la eficacia de agentes terapeuticos. La composicion es administrada a un animal o a un humano con un portador farmaceuticamente aceptable, y opcionalmente con un agente terapeutico, en una cantidad efectiva para modular la expresion de Sindrome de Alcohol Fetal o de Ligando de Sindrome de Alcohol Fetal, para tratar la enfermedad o para modular la eficacia del agente terapeutico.
MXPA03001812A 2000-08-29 2001-06-12 Modulacion de la expresion del sindrome de alcohol fetal y del ligando del sindrome de alcohol fetal.. MXPA03001812A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22892500P 2000-08-29 2000-08-29
PCT/CA2000/001467 WO2001044465A2 (en) 1999-12-13 2000-12-12 Therapeutically useful synthetic oligonucleotides
US09/735,363 US7157436B2 (en) 1999-12-13 2000-12-12 Therapeutically useful synthetic oligonucleotides
US26622901P 2001-02-02 2001-02-02
PCT/CA2001/000845 WO2002018593A2 (en) 2000-08-29 2001-06-12 Modulation of fas and fasl expression

Publications (1)

Publication Number Publication Date
MXPA03001812A true MXPA03001812A (es) 2004-05-21

Family

ID=27426776

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001812A MXPA03001812A (es) 2000-08-29 2001-06-12 Modulacion de la expresion del sindrome de alcohol fetal y del ligando del sindrome de alcohol fetal..

Country Status (6)

Country Link
EP (1) EP1313853B1 (es)
JP (1) JP2004507469A (es)
AU (1) AU6886301A (es)
CA (1) CA2420103A1 (es)
MX (1) MXPA03001812A (es)
WO (1) WO2002018593A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107150A0 (en) * 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
US5643890A (en) * 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
IT1277025B1 (it) * 1995-12-04 1997-11-04 Cooperativa Centro Ricerche Po Classe di oligonucleotidi fosfodiesterici ad attivita' citotossica composizioni farmaceutiche che li contengono e loro uso
AU8408798A (en) * 1997-07-17 1999-02-10 Regents Of The University Of Michigan, The Methods and compositions for inhibiting the proinflammatory response
ES2288883T3 (es) 1999-12-13 2008-02-01 Bioniche Life Sciences Inc. Oligonucleotidos sinteticos utiles terapeuticamente.

Also Published As

Publication number Publication date
AU6886301A (en) 2002-03-13
CA2420103A1 (en) 2002-03-07
WO2002018593A2 (en) 2002-03-07
EP1313853B1 (en) 2012-03-21
JP2004507469A (ja) 2004-03-11
WO2002018593A3 (en) 2002-12-12
EP1313853A2 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
IL264560B (en) Preparations for improved activity to kill mites
MY113488A (en) Compounds with growth hormone releasing properties
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
MY129356A (en) Electrospun pharmaceutical compositions
DE60228721D1 (en) Zellproliferationsinhibitoren mit anti-glypican-3-antikörper
TW200505900A (en) Muscarinic agonists
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
ES2031096T3 (es) Una composicion de implante mejorada a base de estradiol y metodo para su preparacion.
AU7315301A (en) Compounds and compositions for delivering active agents
HK1036969A1 (en) Compounds and compositions for delivering active agents
IL153554A0 (en) Methods and compositions utilizing quinazolinones
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
SE9802208D0 (sv) Novel compounds
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
WO2002043757A3 (de) Arzneimittel zur vermeidung oder behandlung von durch humanen papillomavirus-typ 18-hervorgerufenem tumor
SE9802209D0 (sv) Novel compounds
MXPA03001812A (es) Modulacion de la expresion del sindrome de alcohol fetal y del ligando del sindrome de alcohol fetal..
NO941097D0 (no) Hudregenererende kosmetisk preparat
MXPA01007952A (es) Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.
EP1390388A4 (en) ANTISENSE MODULATION OF INTERFERON GAMMA RECEPTOR 1 EXPRESSION
NZ506406A (en) Compositions comprising Mycobacterium phlei DNA and methods for its use in the treatment of bladder cancer
DE60130253D1 (de) Zusammensetzungen zur verhinderung der adhäsion
AR016067A1 (es) Una composicion anti-pie de atleta, utilizacion de lactosacarosa para preparar una composicion anti-pie de atleta y un metodo para preparar una composicionanti-pie de atleta
IL142295A0 (en) Use of acylcarnitines as antitumour agents

Legal Events

Date Code Title Description
FG Grant or registration